Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy

Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yongxian, Wang, Jiasheng, Pu, Chengfei, Zhao, Kui, Cui, Qu, Wei, Guoqing, Wu, Wenjun, Xiao, Lei, Xiao, Yang, Wang, Jinping, Wu, Zhao, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192928/
https://www.ncbi.nlm.nih.gov/pubmed/29397660
http://dx.doi.org/10.4143/crt.2017.473
Descripción
Sumario:Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time we report a diffuse large B-cell lymphoma patient with terminal ileum involvement obtained rapid remission and developed spontaneous terminal ileal perforation 38 days following CART19 infusion. The late-onset perforation reminds us that, for the safety of CART treatment, more cautions are warranted for the management of delayed GI complications.

Ejemplares similares